Vi använder cookies för att förstå hur du använder vår webbplats och för att förbättra din upplevelse. Detta inkluderar att anpassa innehåll och reklam. Genom att fortsätta använda vår webbplats accepterar du vår användning av Cookies, Privacy Policy Term of use.
Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
9,953 views • February 9, 2022

Pfizer Quietly Adds Warning That 'Unfavorable Pre-Clinical, Clinical Or Safety Data' May Impact Business

Facts Matter
Facts Matter
As we get closer and closer to the day that the FDA has to release its first batch of 55,000 pages of clinical trial documents, it looks like Pfizer is bracing for impact. That’s because it was just revealed that Pfizer updated its fourth-quarter investor report—the section on potential risks to their business. Specifically, they added that in the near future, information regarding the quality of pre-clinical, clinical, or safety data that might be released by an audit or inspection might be a threat to their business. Meanwhile, while I was in Texas, I took the opportunity to sit down and speak with Jim Lamon, the founder of an America-first renewable energy company, and we discussed the way forward for American energy independence. Stay tuned for our newsletter so you won’t miss out on our exclusive videos and private events. Facts Matter is an Epoch Times show available on YouTube. Follow Roman on Instagram: @epoch.times.roman Listen to Podcasts: iTunes Podcast: Spotify Podcast: Google Podcast: Follow EpochTV on social media: Facebook: Twitter: Rumble: Gettr: Gab: Telegram: Parler:
Show All
Comment 0